What did @daviddemesquita actually say?
The creator describes a personal protocol combining BPC-157 at "250 micrograms three times a day" with TB-500 at "5 milligrams" dosed up to four times per week, alongside growth hormone. He claims this stack healed a ruptured hamstring in one week, allowing a 400-pound squat at two weeks and a 500-pound squat for reps one month later. He argues BPC-157 "can be run at much higher dosages than most people are talking about" because it is "so safe and effective."
To be direct: this is one person's anecdote, presented with specific numbers and a dramatic outcome. The specificity gives it the feel of clinical data. It is not. A ruptured hamstring is a serious structural injury, and the timeline described here would be extraordinary even with the best-documented interventions in sports medicine.
Does the science back this up?
Animal data on BPC-157 is genuinely interesting, but human clinical trial evidence is essentially absent. The peptide has not cleared a phase II or phase III trial in humans for musculoskeletal injuries.
BPC-157, a synthetic pentadecapeptide derived from gastric juice, has shown pro-angiogenic and tendon-healing effects in rodent models. Sikiric et al. (2018, Current Pharmaceutical Design) documented accelerated tendon-to-bone healing in rats. TB-500, a synthetic fragment of Thymosin Beta-4, has similarly shown wound-healing and anti-inflammatory activity in animal studies, with Goldstein et al. (2012, Annals of the New York Academy of Sciences) noting its role in actin sequestration and cell migration. These are real biological signals. They are not evidence that a human with a ruptured hamstring will squat 500 pounds one month post-injury. The leap from rodent tendon repair to that claim is enormous, and the creator does not acknowledge it.
What did they get wrong (or right)?
Credit where it is due: the creator correctly notes that TB-500 is typically run at higher loading doses before titrating down, which reflects how it has been used in the broader peptide community and is consistent with its longer half-life compared to BPC-157. That general framing is reasonable.
What is wrong, and worth saying plainly: the claim that BPC-157 is "so safe and effective" justifying higher-than-typical doses is not supported by human safety data. We do not have dose-finding studies in humans. The safety profile comes almost entirely from animal models, and extrapolating that to "run it higher" in people is speculative. Adding exogenous growth hormone to this stack introduces a third compound with its own significant risk profile, including insulin resistance, edema, and joint pain, and the creator presents this combination casually. The one-week hamstring rupture recovery claim is not biologically plausible for a complete rupture by any standard of sports medicine evidence. A grade III hamstring rupture typically requires months of rehabilitation regardless of pharmacological support.
What should you actually know?
BPC-157 and TB-500 are research compounds. They are not FDA-approved for any human indication. They are not available as approved drugs at any pharmacy, and any compounded versions exist in a regulatory gray zone that is worth understanding before use.
The peptide research that does exist, like Zgrajka et al. and the broader Sikiric group's work, is conducted in controlled animal settings with verified compounds and precise dosing. What someone buys through gray-market peptide suppliers may not match labeled concentrations, purity, or sterility standards. That matters a great deal when you are injecting something subcutaneously. The combination of unverified compounds, anecdotal dosing protocols from social media, and the addition of growth hormone represents a stack that carries real unknowns. A 30,000-view TikTok about a one-week hamstring recovery is not a clinical signal. It is a story. Treat it accordingly, and talk to a licensed provider who understands peptide pharmacology before making any decisions based on it.